http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Four quadrant SAZZ-1 Chopper for EV and HEV power train
Yukinori Tsuruta,Martin Pavlovsky,Giuseppe Guidi,Atsuo Kawamura 전력전자학회 2011 ICPE(ISPE)논문집 Vol.2011 No.5
This paper discusses four quadrant SAZZ-1 chopper (Snubber Assisted Zero Voltage and Zero Current Switching) and its direct application to a EV (Electric Vehicle) power train. The performance of SAZZ-1 chopper is demonstrated on several prototypes. The first prototype is a 25 ㎾, 50 ㎑ SAZZ-1 with efficiency in the range between 96 % and 97 %. This was further improved by a redesigned SAZZ-1 chopper which reached even higher efficiency in the range of 97 % to over 98 %. Further on, a new mid-power 30 ㎾ water cooled SAZZ-1 chopper was constructed for KAST (Kanagawa Academy of Science and Technology) advanced EV project. This prototype was used and fully tested in an EV prototype named KAST-EVKana. As discussed, SAZZ-1 topology proved to be well performing in direct EV application.
Jabbour, Elias,Kantarjian, Hagop M.,Saglio, Giuseppe,Steegmann, Juan Luis,Shah, Neil P.,Boqué,, Concepció,n,Chuah, Charles,Pavlovsky, Carolina,Mayer, Jiř,í,Cortes, Jorge,Baccara American Society of Hematology 2014 Blood Vol.123 No.4
<P>This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 DASatinib versus Imatinib Study In treatment-Naive CML patients trial with a minimum follow-up of 3 years. Patients with newly diagnosed CML-CP were randomized to receive 100 mg dasatinib (n = 259) or 400 mg imatinib (n = 260) once daily. The retrospective landmark analysis included patients evaluable at the relevant time point (3, 6, or 12 months). Median time to complete cytogenetic response was 3 vs 6 months with dasatinib vs imatinib. At 3 and 6 months, the proportion of patients with BCR-ABL transcript levels ≤10% was higher in the dasatinib arm. Deeper responses at 3, 6, and 12 months were observed in a higher proportion of patients on dasatinib therapy and were associated with better 3-year progression-free survival and overall survival in both arms. First-line dasatinib resulted in faster and deeper responses compared with imatinib. The achievement of an early molecular response was predictive of improved progression-free survival and overall survival, supporting new milestones for optimal response in patients with early CML-CP treated with tyrosine kinase inhibitors. This study was registered at www.clinicaltrials.gov as NCT00481247.</P>